Novo Nordisk and AWS Bring Agentic AI into Drug Discovery

Agentic AI refers to AI systems capable of taking autonomous actions to achieve specific goals, such as analyzing genetic data to identify new drug targets or proposing therapeutic combinations, thereby accelerating research and development.

Novo Nordisk will leverage AWS cloud services and advanced AI tools, including foundation models and AI agents, to improve drug discovery efficiency, reduce costs, and accelerate time-to-market for new therapies.

This partnership provides a practical model for regional pharma and healthcare companies to adopt AI in their research, potentially boosting local innovation and improving patient outcomes, especially as governments push for digital transformation.

Yes, companies in the region can start with small-scale pilots with cloud providers like AWS to assess benefits, while focusing on building local capabilities and ensuring compliance with health regulations.